Clinical Trials Logo

Clinical Trial Summary

Background: Asthma and COPD are considered different diseases but many patients share characteristics of both entities. This has been termed "COPD-asthma overlap syndrome".

Study objective: To examine: (a) the frequency of the overlap phenotype among patients referred for pulmonary function testing and, (b) the impact of this phenotype on the therapeutic management and the quality of life of these patients as compared with patients with COPD only and asthma only.

Methods:

Type of study: Observational, cross-sectional. Study subjects: Patients referred for pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an informed consent.

Study procedures: Spirometry will be performed before and after the administration of a bronchodilator. Respiratory questionnaire: Questionnaires about smoking habits, past history of asthma and wheezing, current medications and history of exacerbations will be administered at inclusion. Questionnaire on medication utilization will be administered by telephone one month after inclusion. Quality of life: Will be assessed using the Saint George Respiratory Questionnaire (SGRQ).

Working definitions: The following definitions will be adopted: a) COPD only: smoking history > 10 pack/years and post-bronchodilator (BD) FEV1/FVC ratio of < 0.70; b) Asthma only: (1) presence of wheezing in the last year plus a minimum post-BD increase in FEV1 or FVC of 12% and 200 ml; (2) prior physician diagnosis (before age 40); and c) both COPD-Asthma (the overlap group) - the combination of the two.

Outcome measures: The clinical outcome is the prevalence rate of the phenotypes. Patient-reported outcomes will include the utilization of medication, the number of exacerbations, and quality of life.


Clinical Trial Description

Background: Asthma and COPD are considered different diseases but many patients share characteristics of both entities. This has been termed "COPD-asthma overlap syndrome".

Study objective: To examine: (a) the frequency of the overlap phenotype among patients referred for pulmonary function testing and, (b) the impact of this phenotype on the therapeutic management and the quality of life of these patients as compared with patients with COPD only and asthma only.

Methods:

Type of study: Observational, cross-sectional. Study subjects: Patients referred for pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an informed consent.

Study procedures: Spirometry will be performed before and after the administration of a bronchodilator. Respiratory questionnaire: Questionnaires about smoking habits, past history of asthma and wheezing, current medications and history of exacerbations will be administered at inclusion. Questionnaire on medication utilization will be administered by telephone one month after inclusion. Quality of life: Will be assessed using the Saint George Respiratory Questionnaire (SGRQ).

Working definitions: The following definitions will be adopted: a) COPD only: smoking history > 10 pack/years and post-bronchodilator (BD) FEV1/FVC ratio of < 0.70; b) Asthma only: (1) presence of wheezing in the last year plus a minimum post-BD increase in FEV1 or FVC of 12% and 200 ml; (2) prior physician diagnosis (before age 40); and c) both COPD-Asthma (the overlap group) - the combination of the two.

Outcome measures: The clinical outcome is the prevalence rate of the phenotypes. Patient-reported outcomes will include the utilization of medication, the number of exacerbations, and quality of life.

Statistical plan: Sample size: For an estimated prevalence rate of 20%, 246 patients should be recruited with 5% imprecision and 95% degree of confidence. To round up, 250 patients will be included. Statistical methods: Multiple comparisons will be carried out using the one-way ANOVA for continuous variables and chi-squared test (or Fisher Exact Test) for qualitative variables. Multiple logistic regression models will be tested to examine the relation between the "COPD-asthma overlap" phenotype and various independent or predictor variables.

Expected benefits: Data collected could serve to advance the medical community's knowledge pertaining to the COPD-asthma overlap syndrome. Most importantly, however, they will encourage reflection on the best therapeutic options for the patients with the overlap syndrome. Indeed, recommendations on this matter are noticeably absent from the current guidelines proposed to treat and monitor obstructive lung diseases. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02985814
Study type Observational [Patient Registry]
Source Clalit Health Services
Contact
Status Completed
Phase N/A
Start date February 4, 2015
Completion date February 2017

See also
  Status Clinical Trial Phase
Recruiting NCT04142827 - The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX) N/A
Completed NCT05162157 - Home Spirometry in Primary Care: an Implementation Study
Not yet recruiting NCT03249428 - E-Cigarette Inner City RCT N/A
Recruiting NCT05398133 - Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
Recruiting NCT03695276 - Pulmonary Specialist-Health Coach Consult Model Study N/A
Completed NCT03275935 - Evaluation of Inhalation Technique in Patients With COPD, Asthma or ACOS Using a Dry Powder Device (DPI) N/A
Completed NCT05564156 - Development and Evaluation of Clinical Pharmacy Services in Respiratory Diseases N/A
Enrolling by invitation NCT03056066 - Accuracy of Spircare Device as Compared to the Conventional Plethysmograph
Completed NCT03137303 - Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study) Phase 3
Not yet recruiting NCT05732922 - ORCHARD- Optimising Home Assessment of Rural Patients N/A
Completed NCT05397275 - The Effect of Progressive Relaxation and Breathing Exercise on Sleep Quality and Exercise Self-Efficacy in Patients With COPD N/A
Completed NCT03739359 - The Role of Gas Flow in Transnasal Pulmonary Aerosol Delivery: A Double-blinded, Randomized Controlled Trial N/A
Completed NCT03395418 - Evaluation of the Right Use of Inhaled Therapeutics